AR043450A1 - Derivados de g-lactama como agonista de la prostaglandina - Google Patents

Derivados de g-lactama como agonista de la prostaglandina

Info

Publication number
AR043450A1
AR043450A1 ARP040100655A ARP040100655A AR043450A1 AR 043450 A1 AR043450 A1 AR 043450A1 AR P040100655 A ARP040100655 A AR P040100655A AR P040100655 A ARP040100655 A AR P040100655A AR 043450 A1 AR043450 A1 AR 043450A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
gamma
heterocycloalkyl
heteroaryl
Prior art date
Application number
ARP040100655A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR043450A1 publication Critical patent/AR043450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a derivados de gamma-lactama, en especial para utilizar como medicamentos, así como también como formulaciones farmacéuticas que contienen dichos derivados de gamma-lactama. Los derivados de gamma-lactama son útiles en el tratamiento y/o prevención del asma, hipertensión, osteoporosis, disfunción sexual y trastornos de la fertilidad. Reivindicación 1: Un dieno de gamma-lactama de fórmula (1) donde A se selecciona entre alquilo (C1-4), arilo, heteroarilo, cicloalquilo(C3-6) y heterocicloalquilo (C3-6), B es C(O)Z, donde Z se selecciona de hidroxi, alcoxi, alquilo (C1-6)heteroalquilo(C1-6); y NR1R2 donde R1 y R2 se seleccionan independientemente de H, cicloalquilo (C3-6), heterocicloalquilo (C3-6), arilalquilo(C1-6) y heteroarilalquilo (C1-6); D se selecciona de H, halógeno y alquilo (C1-6); E se selecciona de H y alquilo (C1-6); G se selecciona de H, alquilo (C1-6)(, alquenilo (C2-6), alquinilo (C2-6), cicloalquilo (C3-6)alquilo(C1-6), cicloalquilo (C3-6), heterocicloalquilo (C3-6), arilalquilo (C1-6), heteroarilalquilo (C1-6), arilo y heteroarilo; o E y G forman, junto con el átomo al que se encuentran unidos, un anillo cicloalquilo (C3-6); J, K y L se seleccionan independientemente de H, halógeno, alquilo (C1-6), arilo y heteroarilo; M se selecciona de OH y H; n es un número entero seleccionado entre 0 y 1; los doble enlaces (a) y (b) pueden ser independientemente enlaces Z o E.
ARP040100655A 2003-03-03 2004-03-02 Derivados de g-lactama como agonista de la prostaglandina AR043450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45182903P 2003-03-03 2003-03-03

Publications (1)

Publication Number Publication Date
AR043450A1 true AR043450A1 (es) 2005-07-27

Family

ID=32962645

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100655A AR043450A1 (es) 2003-03-03 2004-03-02 Derivados de g-lactama como agonista de la prostaglandina

Country Status (11)

Country Link
US (1) US7276531B2 (es)
EP (1) EP1603874B1 (es)
JP (1) JP4662926B2 (es)
AR (1) AR043450A1 (es)
AT (1) ATE394372T1 (es)
AU (1) AU2004216857A1 (es)
CA (1) CA2513652A1 (es)
DE (1) DE602004013559D1 (es)
ES (1) ES2305779T3 (es)
NO (1) NO20054441L (es)
WO (1) WO2004078103A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841733A2 (en) 2004-11-08 2007-10-10 Allergan, Inc. Substituted pyrrolidone compounds as prostaglandin ep4 agonists
BRPI0611079A2 (pt) 2005-06-03 2010-08-03 Ono Pharmaceutical Co agentes para a regeneração e/ou proteção de nervos
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
EP2753640B1 (en) 2011-09-08 2016-03-09 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
CN106748951B (zh) 2012-07-19 2020-07-24 开曼化学股份有限公司 作为在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物
KR102221534B1 (ko) * 2012-08-21 2021-02-26 알레간 인코포레이티드 치환된 감마 락탐의 합성을 위한 공정
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP6368351B2 (ja) 2013-03-15 2018-08-01 ケイマン ケミカル カンパニー， インコーポレーテッド ジフルオロラクタムアナログを合成する方法
EP3235817B1 (en) * 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
KR20160048054A (ko) * 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
WO2018015280A1 (en) 2016-07-21 2018-01-25 Unilever Plc 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections
WO2018015279A1 (en) 2016-07-21 2018-01-25 Unilever Plc Lactams for the treatment of respiratory tract infections
CN109475527A (zh) 2016-07-21 2019-03-15 荷兰联合利华有限公司 用于治疗皮肤损伤的内酰胺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198503B (en) 1987-03-24 1989-10-30 Chinoin Gyogyszer Es Vegyeszet Process for producing triphenyl phosphonium salts
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
US6262293B1 (en) 1997-12-25 2001-07-17 Ono Pharmaceutical Co., Ltd. ω-Cycloalkly-prostaglandin e2 derivatives
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
US20010006980A1 (en) * 1998-10-15 2001-07-05 Harada Shun-Ichi Methods for stimulating bone formation
EE200200355A (et) 1999-12-22 2003-10-15 Pfizer Products Inc. EP4 retseptori selektiivsed agonistid osteoporoosi raviks
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
MXPA03004623A (es) 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
CA2451393C (en) * 2001-07-16 2011-01-04 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
EP1409455B1 (en) * 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandin analogues-as ep4 receptor agonists

Also Published As

Publication number Publication date
EP1603874A2 (en) 2005-12-14
JP4662926B2 (ja) 2011-03-30
DE602004013559D1 (de) 2008-06-19
US7276531B2 (en) 2007-10-02
WO2004078103A2 (en) 2004-09-16
EP1603874B1 (en) 2008-05-07
ATE394372T1 (de) 2008-05-15
JP2006519245A (ja) 2006-08-24
WO2004078103A3 (en) 2004-10-28
CA2513652A1 (en) 2004-09-16
US20060194865A1 (en) 2006-08-31
AU2004216857A1 (en) 2004-09-16
NO20054441L (no) 2005-09-26
ES2305779T3 (es) 2008-11-01

Similar Documents

Publication Publication Date Title
AR043450A1 (es) Derivados de g-lactama como agonista de la prostaglandina
UY28374A1 (es) Agentes terapéuticos
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
CR8544A (es) Compuestos de quinolina sustituidos
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
TNSN07005A1 (fr) Analogues tetrapeptidiques
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
AR049262A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
UY28839A1 (es) Agentes terapeuticos
NO20085323L (no) Smeltede, tricykliske sulfonamidinhibitorer av gammasekretase
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
MX2007004273A (es) Nuevas azaindol-tiazolinonas como agentes anti-cancerosos.
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
UY28377A1 (es) Agentes terapeuticos
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
ATE464296T1 (de) Selektive nichtsteroidale glucocorticoid-rezeptor-modulatoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal
FB Suspension of granting procedure